Baird Financial Group
TARA icon

Baird Financial Group’s Protara Therapeutics TARA Stock Holding History

Baird Financial Group’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-336
Closed -$108K – 1226
2016
Q2 		$108K Sell
336
-162
-33% -$48.5K ﹤0.01% 1171
2016
Q1 		$154K Buy
+498
New +$161K ﹤0.01% 1177

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Baird Financial Group's TARA Position: Q3 2016 in Review

Baird Financial Group sold out of Protara Therapeutics (TARA) in Q3 2016, closing a stake of 336 shares — an estimated $108K sold.

Baird Financial Group first reported a position in TARA in Q1 2016 and held it in 2 quarters. The position peaked at $154K in Q1 2016. 29 funds tracked by Wall St. Rank hold TARA as of Q3 2016.

  • Baird Financial Group reported no remaining Protara Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Baird Financial Group sold 336 Protara Therapeutics shares in Q3 2016, an estimated $108K.
  • Baird Financial Group first reported a position in Protara Therapeutics in Q1 2016 and held it in 2 quarters.
  • Baird Financial Group's Protara Therapeutics position peaked at $154K in Q1 2016.
  • 29 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2016.

Based on Baird Financial Group's 13F filing for Q3 2016, filed 10 Nov 2016.